메뉴 건너뛰기




Volumn 50, Issue 1, 2011, Pages 40-44

Significance of clopidogrel resistance related to the stent-assisted angioplasty in patients with atherosclerotic cerebrovascular disease

Author keywords

Clopidogrel ; Neurointervention ; Resistance ; Stent

Indexed keywords

ABCIXIMAB; CLOPIDOGREL;

EID: 79961180319     PISSN: 20053711     EISSN: 15987876     Source Type: Journal    
DOI: 10.3340/jkns.2011.50.1.40     Document Type: Article
Times cited : (17)

References (36)
  • 1
    • 52449085759 scopus 로고    scopus 로고
    • A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: Results of the OPTIMUS-2 study
    • Angiolillo DJ, Capranzano P, Goto S, Aslam M, Desai B, Charlton RK, et al.: A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study. Eur Heart J 29: 2202-2211, 2008
    • (2008) Eur Heart J , vol.29 , pp. 2202-2211
    • Angiolillo, D.J.1    Capranzano, P.2    Goto, S.3    Aslam, M.4    Desai, B.5    Charlton, R.K.6
  • 3
    • 57049187605 scopus 로고    scopus 로고
    • Interaction between statins and clopidogrel: Is there anything clinically relevant?
    • Bhindi R, Ormerod O, Newton J, Banning AP, Testa L: Interaction between statins and clopidogrel: is there anything clinically relevant? QJM 101: 915-925, 2008
    • (2008) QJM , vol.101 , pp. 915-925
    • Bhindi, R.1    Ormerod, O.2    Newton, J.3    Banning, A.P.4    Testa, L.5
  • 4
    • 0037588974 scopus 로고    scopus 로고
    • Inactivation of the human P2Y12 receptor by thiol reagents requires interaction with both extracellular cystein residues, Cys17 and Cys270
    • Ding Z, Kim S, Dorsam RT, Jin J, Kunapuli SP: Inactivation of the human P2Y12 receptor by thiol reagents requires interaction with both extracellular cystein residues, Cys17 and Cys270. Blood 101: 3908-3914, 2003
    • (2003) Blood , vol.101 , pp. 3908-3914
    • Ding, Z.1    Kim, S.2    Dorsam, R.T.3    Jin, J.4    Kunapuli, S.P.5
  • 7
    • 33749503499 scopus 로고    scopus 로고
    • Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation
    • Geisler T, Langer H, Wydymus M, Göhring K, Zürn C, Bigalke B, et al.: Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur Heart J 27: 2420-2425, 2006
    • (2006) Eur Heart J , vol.27 , pp. 2420-2425
    • Geisler, T.1    Langer, H.2    Wydymus, M.3    Göhring, K.4    Zürn, C.5    Bigalke, B.6
  • 8
    • 34548849756 scopus 로고    scopus 로고
    • Preliminary experience with intravenous P2Y12 platelet receptor inhibition as an adjunct to reduced-dose alteplase during acute myocardial infarction: Results of the Safety, Tolerability and Effect on Patency in Acute Myocardial Infarction (STEP-AMI) angiographic trial
    • Greenbaum AB, Ohman EM, Gibson CM, Borzak S, Stebbins AL, Lu M, et al.: Preliminary experience with intravenous P2Y12 platelet receptor inhibition as an adjunct to reduced-dose alteplase during acute myocardial infarction: results of the Safety, Tolerability and Effect on Patency in Acute Myocardial Infarction (STEP-AMI) angiographic trial. Am Heart J 154: 702-709, 2007
    • (2007) Am Heart J , vol.154 , pp. 702-709
    • Greenbaum, A.B.1    Ohman, E.M.2    Gibson, C.M.3    Borzak, S.4    Stebbins, A.L.5    Lu, M.6
  • 9
    • 68149180722 scopus 로고    scopus 로고
    • Recent developments in clopidogrel pharmacology and their relation to clinical outcomes
    • Gurbel PA, Antonino MJ, Tantry US: Recent developments in clopidogrel pharmacology and their relation to clinical outcomes. Expert Opin Drug Metab Toxicol 5: 989-1004, 2009
    • (2009) Expert Opin Drug Metab Toxicol , vol.5 , pp. 989-1004
    • Gurbel, P.A.1    Antonino, M.J.2    Tantry, U.S.3
  • 10
    • 73949112820 scopus 로고    scopus 로고
    • Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: The ONSET/OFFSET study
    • Gurbel PA, Bliden KP, Butler K, Tantry US, Gesheff T, Wei C, et al.: Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation 120: 2577-2585, 2009
    • (2009) Circulation , vol.120 , pp. 2577-2585
    • Gurbel, P.A.1    Bliden, K.P.2    Butler, K.3    Tantry, U.S.4    Gesheff, T.5    Wei, C.6
  • 11
    • 33646261670 scopus 로고    scopus 로고
    • Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: A double-blind comparison to clopidogrel with aspirin
    • Husted S, Emanuelsson H, Heptinstall S, Sandset PM, Wickens M, Peters G: Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J 27: 1038-1047, 2006
    • (2006) Eur Heart J , vol.27 , pp. 1038-1047
    • Husted, S.1    Emanuelsson, H.2    Heptinstall, S.3    Sandset, P.M.4    Wickens, M.5    Peters, G.6
  • 12
    • 62549101321 scopus 로고    scopus 로고
    • Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: Results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients with Clopidogrel Resistance) randomized study
    • Jeong YH, Lee SW, Choi BR, Kim IS, Seo MK, Kwak CH, et al.: Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients with Clopidogrel Resistance) randomized study. J Am Coll Cardiol 53: 1101-1109, 2009
    • (2009) J Am Coll Cardiol , vol.53 , pp. 1101-1109
    • Jeong, Y.H.1    Lee, S.W.2    Choi, B.R.3    Kim, I.S.4    Seo, M.K.5    Kwak, C.H.6
  • 13
    • 33646732608 scopus 로고    scopus 로고
    • Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease
    • Jernberg T, Payne CD, Winters KJ, Darstein C, Brandt JT, Jakubowski JA, et al.: Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J 27: 1166-1173, 2006
    • (2006) Eur Heart J , vol.27 , pp. 1166-1173
    • Jernberg, T.1    Payne, C.D.2    Winters, K.J.3    Darstein, C.4    Brandt, J.T.5    Jakubowski, J.A.6
  • 14
    • 77958449480 scopus 로고    scopus 로고
    • Is clopidogrel premedication useful to reduce thromboembolic events during coil embolization for unruptured intracranial aneurysms?
    • discussion 1376
    • Kang HS, Han MH, Kwon BJ, Jung C, Kim JE, Kwon OK, et al.: Is clopidogrel premedication useful to reduce thromboembolic events during coil embolization for unruptured intracranial aneurysms? Neurosurgery 67: 1371-1376; discussion 1376, 2010
    • (2010) Neurosurgery , vol.67 , pp. 1371-1376
    • Kang, H.S.1    Han, M.H.2    Kwon, B.J.3    Jung, C.4    Kim, J.E.5    Kwon, O.K.6
  • 15
    • 39049175606 scopus 로고    scopus 로고
    • "Smoker's paradox" in patients with acute myocardial infarction receiving primary coronary intervention
    • Katayama T, Iwasaki Y, Yamamoto T, Yoshioka M, Nakashima H, Suzuki S, et al.: ["Smoker's paradox" in patients with acute myocardial infarction receiving primary coronary intervention]. J Cardiol 48: 193-200, 2006
    • (2006) J Cardiol , vol.48 , pp. 193-200
    • Katayama, T.1    Iwasaki, Y.2    Yamamoto, T.3    Yoshioka, M.4    Nakashima, H.5    Suzuki, S.6
  • 16
    • 60749114799 scopus 로고    scopus 로고
    • Interindividual variability in the response to oral antiplatelet drugs: A position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology
    • Kuliczkowski W, Witkowski A, Polonski L, Watala C, Filipiak K, Budaj A, et al.: Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology. Eur Heart J 30: 426-435, 2009
    • (2009) Eur Heart J , vol.30 , pp. 426-435
    • Kuliczkowski, W.1    Witkowski, A.2    Polonski, L.3    Watala, C.4    Filipiak, K.5    Budaj, A.6
  • 17
    • 0003306666 scopus 로고    scopus 로고
    • The antiplatelet activity of clopidogrel is inhibited by atorvastatin but not by pravastatin
    • Lau WC, Waskell LA, Neer CJ, Carville DGM, Bates ER: The antiplatelet activity of clopidogrel is inhibited by atorvastatin but not by pravastatin. Circulation 102: 2086, 2000
    • (2000) Circulation , vol.102 , pp. 2086
    • Lau, W.C.1    Waskell, L.A.2    Neer, C.J.3    Carville, D.G.M.4    Bates, E.R.5
  • 18
    • 0037422534 scopus 로고    scopus 로고
    • Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: A new drug-drug interaction
    • Lau WC, Waskell LA, Watkins PB, Neer CJ, Horowitz K, Hopp AS, et al.: Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation 107: 32-37, 2003
    • (2003) Circulation , vol.107 , pp. 32-37
    • Lau, W.C.1    Waskell, L.A.2    Watkins, P.B.3    Neer, C.J.4    Horowitz, K.5    Hopp, A.S.6
  • 19
    • 78951472564 scopus 로고    scopus 로고
    • The effect of St John's Wort on the pharmacodynamic response of clopidogrel in hyporesponsive volunteers and patients: Increased platelet inhibition by enhancement of CYP3A4 metabolic activity
    • Lau WC, Welch TD, Shields T, Rubenfire M, Tantry US, Gurbel PA: The effect of St John's Wort on the pharmacodynamic response of clopidogrel in hyporesponsive volunteers and patients: increased platelet inhibition by enhancement of CYP3A4 metabolic activity. J Cardiovasc Pharmacol 57: 86-93, 2011
    • (2011) J Cardiovasc Pharmacol , vol.57 , pp. 86-93
    • Lau, W.C.1    Welch, T.D.2    Shields, T.3    Rubenfire, M.4    Tantry, U.S.5    Gurbel, P.A.6
  • 20
    • 49749114862 scopus 로고    scopus 로고
    • Dual antiplatelet therapy monitoring for neurointerventional procedures using a point-of-care platelet function test: A single-center experience
    • Lee DH, Arat A, Morsi H, Shaltoni H, Harris JR, Mawad ME: Dual antiplatelet therapy monitoring for neurointerventional procedures using a point-of-care platelet function test: a single-center experience. AJNR Am J Neuroradiol 29: 1389-1394, 2008
    • (2008) AJNR Am J Neuroradiol , vol.29 , pp. 1389-1394
    • Lee, D.H.1    Arat, A.2    Morsi, H.3    Shaltoni, H.4    Harris, J.R.5    Mawad, M.E.6
  • 21
    • 40749126089 scopus 로고    scopus 로고
    • Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus: The DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Diabetic Patients)
    • Lee SW, Park SW, Kim YH, Yun SC, Park DW, Lee CW, et al.: Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus: the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Diabetic Patients). J Am Coll Cardiol 51: 1181-1187, 2008
    • (2008) J Am Coll Cardiol , vol.51 , pp. 1181-1187
    • Lee, S.W.1    Park, S.W.2    Kim, Y.H.3    Yun, S.C.4    Park, D.W.5    Lee, C.W.6
  • 22
    • 8344221349 scopus 로고    scopus 로고
    • Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarc tion
    • Matetzky S, Shenkman B, Guetta V, Shechter M, Bienart R, Goldenberg I, et al.: Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarc tion. Circulation 109: 3171-3175, 2004
    • (2004) Circulation , vol.109 , pp. 3171-3175
    • Matetzky, S.1    Shenkman, B.2    Guetta, V.3    Shechter, M.4    Bienart, R.5    Goldenberg, I.6
  • 23
    • 36949002072 scopus 로고    scopus 로고
    • Effect of cilostazol on in-stent neointimal hyperplasia after coronary artery stenting: A quantitative coronary angiography and volumetric intravascular ultrasound study
    • Min PK, Jung JH, Ko YG, Choi D, Jang Y, Shim WH: Effect of cilostazol on in-stent neointimal hyperplasia after coronary artery stenting: a quantitative coronary angiography and volumetric intravascular ultrasound study. Circ J 71: 1685-1690, 2007
    • (2007) Circ J , vol.71 , pp. 1685-1690
    • Min, P.K.1    Jung, J.H.2    Ko, Y.G.3    Choi, D.4    Jang, Y.5    Shim, W.H.6
  • 24
    • 67649158245 scopus 로고    scopus 로고
    • Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38: An application of the classification system from the universal definition of myocardial infarction
    • Morrow DA, Wiviott SD, White HD, Nicolau JC, Bramucci E, Murphy SA, et al.: Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38: an application of the classification system from the universal definition of myocardial infarction. Circulation 119: 2758-2764, 2009
    • (2009) Circulation , vol.119 , pp. 2758-2764
    • Morrow, D.A.1    Wiviott, S.D.2    White, H.D.3    Nicolau, J.C.4    Bramucci, E.5    Murphy, S.A.6
  • 25
    • 67650901939 scopus 로고    scopus 로고
    • Factors influencing clopidogrel efficacy in patients with stable coronary artery disease undergoing elective percutaneous coronary intervention: Statin's advantage and the smoking "paradox"
    • Motovska Z, Widimsky P, Petr R, Bilkova D, Marinov I, Simek S, et al.: Factors influencing clopidogrel efficacy in patients with stable coronary artery disease undergoing elective percutaneous coronary intervention: statin's advantage and the smoking "paradox". J Cardiovasc Pharmacol 53: 368-372, 2009
    • (2009) J Cardiovasc Pharmacol , vol.53 , pp. 368-372
    • Motovska, Z.1    Widimsky, P.2    Petr, R.3    Bilkova, D.4    Marinov, I.5    Simek, S.6
  • 26
    • 39649097856 scopus 로고    scopus 로고
    • Prevalence and risk factors for aspirin and clopidogrel resistance in cerebrovascular stenting
    • Prabhakaran S, Wells KR, Lee VH, Flaherty CA, Lopes DK: Prevalence and risk factors for aspirin and clopidogrel resistance in cerebrovascular stenting. AJNR Am J Neuroradiol 29: 281-285, 2008
    • (2008) AJNR Am J Neuroradiol , vol.29 , pp. 281-285
    • Prabhakaran, S.1    Wells, K.R.2    Lee, V.H.3    Flaherty, C.A.4    Lopes, D.K.5
  • 27
    • 78549231969 scopus 로고    scopus 로고
    • Anti-platelet drug resistance in the prediction of thromboembolic complications after neurointervention
    • Ryu DS, Hong CK, Sim YS, Kim CH, Jung JY, Joo JY: Anti-platelet drug resistance in the prediction of thromboembolic complications after neurointervention. J Korean Neurosurg Soc 48: 319-324, 2010
    • (2010) J Korean Neurosurg Soc , vol.48 , pp. 319-324
    • Ryu, D.S.1    Hong, C.K.2    Sim, Y.S.3    Kim, C.H.4    Jung, J.Y.5    Joo, J.Y.6
  • 29
    • 10644264277 scopus 로고    scopus 로고
    • Cilostazol, clopidogrel or ticlopidine to prevent sub-acute stent thrombosis: A meta-analysis of randomized trials
    • Schleinitz MD, Olkin I, Heidenreich PA: Cilostazol, clopidogrel or ticlopidine to prevent sub-acute stent thrombosis: a meta-analysis of randomized trials. Am Heart J 148: 990-997, 2004
    • (2004) Am Heart J , vol.148 , pp. 990-997
    • Schleinitz, M.D.1    Olkin, I.2    Heidenreich, P.A.3
  • 30
    • 35548933800 scopus 로고    scopus 로고
    • Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes
    • Storey RF, Husted S, Harrington RA, Heptinstall S, Wilcox RG, Peters G, et al.: Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol 50: 1852-1856, 2007
    • (2007) J Am Coll Cardiol , vol.50 , pp. 1852-1856
    • Storey, R.F.1    Husted, S.2    Harrington, R.A.3    Heptinstall, S.4    Wilcox, R.G.5    Peters, G.6
  • 31
    • 0035085132 scopus 로고    scopus 로고
    • Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes
    • Storey RF, Oldroyd KG, Wilcox RG: Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. Thromb Haemost 85: 401-407, 2001
    • (2001) Thromb Haemost , vol.85 , pp. 401-407
    • Storey, R.F.1    Oldroyd, K.G.2    Wilcox, R.G.3
  • 33
    • 34248397644 scopus 로고    scopus 로고
    • A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days
    • von Beckerath N, Kastrati A, Wieczorek A, Pogatsa-Murray G, Sibbing D, Graf I, et al.: A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days. Eur Heart J 28: 1814-1819, 2007
    • (2007) Eur Heart J , vol.28 , pp. 1814-1819
    • von Beckerath, N.1    Kastrati, A.2    Wieczorek, A.3    Pogatsa-Murray, G.4    Sibbing, D.5    Graf, I.6
  • 34
    • 23644443846 scopus 로고    scopus 로고
    • Impact of smoking status on outcomes of primary coronary intervention for acute myocardial infarction--the smoker's paradox revisited
    • Weisz G, Cox DA, Garcia E, Tcheng JE, Griffin JJ, Guagliumi G, et al.: Impact of smoking status on outcomes of primary coronary intervention for acute myocardial infarction--the smoker's paradox revisited. Am Heart J 150: 358-364, 2005
    • (2005) Am Heart J , vol.150 , pp. 358-364
    • Weisz, G.1    Cox, D.A.2    Garcia, E.3    Tcheng, J.E.4    Griffin, J.J.5    Guagliumi, G.6
  • 36
    • 37349111065 scopus 로고    scopus 로고
    • Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: The Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial
    • Wiviott SD, Trenk D, Frelinger AL, O'Donoghue M, Neumann FJ, Michelson AD, et al.: Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation 116: 2923-2932, 2007
    • (2007) Circulation , vol.116 , pp. 2923-2932
    • Wiviott, S.D.1    Trenk, D.2    Frelinger, A.L.3    O'Donoghue, M.4    Neumann, F.J.5    Michelson, A.D.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.